Dosage and curative effect of blood coagulation factor VIII in the prevention and treatment of haemophilia A in children.
10.3969/j.issn.1672-7347.2014.08.013
- Author:
Yujing WEI
1
;
Yanhui HUANG
;
Baohua ZHAI
;
Juhong YU
;
Caishui WAN
;
Tingting LIU
;
Chenghao JIN
;
Hongbo CHENG
Author Information
1. Hemophilia Information Management Center of Jiangxi Province, Jiangxi Provincial People's Hospital, Nanchang 330006, China.
- Publication Type:Journal Article
- MeSH:
Blood Coagulation;
Child;
Factor VIII;
administration & dosage;
therapeutic use;
Hemophilia A;
therapy;
Hemorrhage;
prevention & control;
Humans
- From:
Journal of Central South University(Medical Sciences)
2014;39(8):831-834
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the correlation between dosage and curative effect of blood coagulation factor VIII in the prevention and treatment of haemophilia A in children and to determine the suitable dose for prevention of hemophilia in developing countries.
METHODS:For different body weights of child patient, every time we used the same dosage of blood coagulation factor VIII (250 U each time, 3 times a week) and observed and recorded the number of hemorrhages in child patients. Then we compared the number of hemorrhages with children without treatment to determine the curative effect. According to the different body weights, we calculated the dosage of VIII factor of blood coagulation per kilogram (hereinafter referred to as the dose), and used Spearman correlation coefficient to study the correlation between dose and curative effect.
RESULTS:The number of hemorrhages in 58 child patients before the treatment was 4.36 ± 1.78, while after the treatment was 2.22 ± 1.04 (t=7.91, P<0.001). The Spearman correlation coefficient of child patients of 5-10 U/kg was -0.421 (P=0.005); the Spearman correlation coefficient of child patients of 10-15 U/kg was -0.331 (P=0.030); the Spearman correlation coefficient of child patients over 15 U/kg was -0.16 (P=0.325).
CONCLUSION:Prevention and treatment can significantly reduce the times of hemorrhage in hemophilia patients.
